Vicki Goodman, M.D. is Vice President, Head of New Asset Development Teams at Bristol-Myers Squibb. She is a hematologist and medical oncologist with 15 years of drug development experience in both government and industry. Following training in internal medicine and hematology/oncology at the University of Michigan, she served as a medical officer at FDA for over two years and subsequently worked at GlaxoSmithKline (GSK) for eight years. While at GSK, Vicki took on roles of increasing responsibility and worked on a range of projects including pazopanib (Votrient) and dabrafenib (Tafinlar), alone and in combination with trametinib (Mekinist). She also led the development of several early to mid-stage oncology drug candidates. She joined Bristol-Myers Squibb in January 2015 as Vice President, Development Leader for Opdivo/Yervoy in Melanoma and GU tumors. In this role, she oversaw the approval of the first I-O combination (Opdivo and Yervoy) in advanced melanoma, approval of Opdivo in adjuvant melanoma, RCC and bladder cancer, and the initiation of several key phase 3 programs. In July 2017, she was appointed to her current role, overseeing a portfolio of experimental assets between proof of concept and fist regulatory approval.
Vicki was profiled in Fierce Women in Biopharma in 2016 and recognized for her contributions to oncology development by Gilda’s Club NYC at their annual benefit luncheon in 2017. She has an interest in mentoring talented women to be the next generation of senior R&D leaders and also serves as a senior advisor to the BMS Network of Women (B-NOW).